Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type( C4 h/ n# o5 U- C$ C) X1 @
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
% y' p8 e: ]8 v" _- e0 b+ Author Affiliations- A9 |; o( A+ m9 [! x. m, x! e
! d f' r+ V; Z' [
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 1 P5 [( a. K5 Q+ H) U0 c# h
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
6 o4 q! h0 C; Z" h' K t8 F; B6 ^3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
C3 W+ ~# b2 n8 R4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
5 j; V ]$ e4 k5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan + K9 h, v6 @/ H" n# ~- Y$ D- N
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
1 Q# i0 @& N# q1 r( c7Kinki University School of Medicine, Osaka 589-8511, Japan ! J: h& D. E/ u* ?" M0 C5 T
8Izumi Municipal Hospital, Osaka 594-0071, Japan 2 L8 q0 k( m- e/ `2 |
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
( u9 a8 @# u2 d9 aCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
. \9 f& ^& Q6 T) n) `AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
3 v/ c! y9 }+ ]; P
1 l+ e" @9 V6 g |